Business
Completion of Acquisition
Completion of Acquisition.
About this update from Ekf Diagnostics Holdings Plc
[{"type":"text","content":"\n RNS Number : 7805T EKF Diagnostics Holdings PLC 04 October 2010 \n \n\nEKF Diagnostics Holdings plc\n(\"EKF\" or the \"Company\")\n \nCompletion of the Acquisition of Quotient Diagnostics Limited, \nDirector's Dealing and Total Voting Rights\n \n \nCompletion of the Acquisition of Quotient Diagnostics Limited\n \nEKF Diagnostics Holdings plc (AIM: EKF), which has recently refocused on the in-vitro diagnostic devices market, announces that it has today completed the acquisition of the entire issued share capital of Quotient Diagnostics Limited (\"Quotient\").\n \nThe 15,507,153 new ordinary shares in the Company which were issued to satisfy the initial consideration for Quotient were admitted to trading on AIM at 8.00 a.m. this morning. \n \nDirectors' Dealing\n \nFollowing the issue of the new ordinary shares, David Evans, Executive Chairman of the Company, now holds a total of 1,279,288 ordinary shares in the Company representing approximately 0.81 per cent. of the issued share capital. \n \nTotal Voting Rights\n \nIn accordance with the Financial Services Authority's Disclosure and Transparency Rules, EKF advises that, following the admission of the new ordinary shares, as at the date of this announcement it has a single class of shares in issue which are admitted to trading on AIM being ordinary shares and that there are 157,934,459 ordinary shares in issue, each carrying one vote per ordinary share. The Company does not hold any ordinary shares in treasury.\n \nThe total number of voting rights in the Company's ordinary shares is 157,934,459 which may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Disclosure and Transparency Rules.\nEnquiries:\n \n\n\n\n\nEKF Diagnostics Holdings plc\nJulian Baines, CEO\nPaul Foulger, FD\n \n\n\nMob: 07788 420 859\nTel: 020 7823 1733\n \n\n\n\n\nZeus Capital - Nominated Adviser and Joint Broker\nRoss Andrews\nTom Rowley\n \n\n\nTel: 0161 831 1512\n\n\n\n\nMatrix Corporate Capital LLP - Joint Broker\n\n\nTel: 020 3206 7000\n\n\n\n\nRobert Naylor\nStephen Waterman\n \n\n\n\n\n\n\n\nWalbrook PR\nPaul McManus\n \n\n\nTel: 020 7933 8...